Literature DB >> 19567506

Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study.

D Gareth R Evans1, Fiona Lennard, Linda J Pointon, Susan J Ramus, Simon A Gayther, Nayanta Sodha, Gek E Kwan-Lim, Martin O Leach, Ruth Warren, Deborah Thompson, Douglas F Easton, Rosalind Eeles.   

Abstract

INTRODUCTION: A UK multicenter study compared the performance of contrast enhanced-magnetic resonance imaging with X-Ray Mammography in women at high-risk of breast cancer commencing in 1997. Selection criteria were used to identify women with at least 0.9% annual risk of breast cancer.
METHODS: Women at high breast cancer risk, with a strong family history and/or high probability of a BRCA1/BRCA2/TP53 mutation, were recruited from 22 centers. Those not known as gene carriers were asked to give a blood sample, which was tested anonymously for mutations. Women ages 35 to 49 years were offered annual screening for 2 to 7 years. Study eligibility at entry was assessed retrospectively by detailed examination of pedigrees and overall eligibility accounting for computer risk assessment and mutation results.
RESULTS: Seventy-eight of 837 (9%) women entered for screening were ineligible using the strict entry criteria. Thirty-nine cancers were detected in 1,869 women-years in study (incidence 21 per 1,000). Including 3,561 further years follow-up, 28 more breast cancers were identified (12 of 1,000). Incidence rates for 759 eligible women were 22 of 1,000 in study and 13 of 1,000 in total follow-up, compared with 9 of 1,000 and 4 of 1,000, respectively, in 78 ineligible women. Breast cancer rates were higher for BRCA2 than BRCA1 after testing anonymized samples in this selected population at 65 of 1,000 in study and 36 of 1,000 in total follow-up for BRCA2 compared with 44 of 1,000 and 27 of 1,000 for BRCA1.
CONCLUSIONS: Strict enforcement of study criteria would have minimally improved the power of the study, whereas testing for BRCA1/2 in advance would have substantially increased the detection rates.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19567506      PMCID: PMC2869031          DOI: 10.1158/1055-9965.EPI-09-0138

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  22 in total

Review 1.  Clinical practice. Management of an inherited predisposition to breast cancer.

Authors:  Mark Robson; Kenneth Offit
Journal:  N Engl J Med       Date:  2007-07-12       Impact factor: 91.245

2.  Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer.

Authors:  Christiane K Kuhl; Simone Schrading; Claudia C Leutner; Nuschin Morakkabati-Spitz; Eva Wardelmann; Rolf Fimmers; Walther Kuhn; Hans H Schild
Journal:  J Clin Oncol       Date:  2005-11-20       Impact factor: 44.544

3.  Accuracy of cancer family histories: comparison of two breast cancer syndromes.

Authors:  Katherine A Schneider; Lisa M DiGianni; Andrea Farkas Patenaude; Neil Klar; Jill E Stopfer; Kathleen A Calzone; Frederick P Li; Barbara L Weber; Judy E Garber
Journal:  Genet Test       Date:  2004

4.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

5.  Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).

Authors:  M O Leach; C R M Boggis; A K Dixon; D F Easton; R A Eeles; D G R Evans; F J Gilbert; I Griebsch; R J C Hoff; P Kessar; S R Lakhani; S M Moss; A Nerurkar; A R Padhani; L J Pointon; D Thompson; R M L Warren
Journal:  Lancet       Date:  2005 May 21-27       Impact factor: 79.321

6.  Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Authors:  Antonis C Antoniou; Amanda B Spurdle; Olga M Sinilnikova; Sue Healey; Karen A Pooley; Rita K Schmutzler; Beatrix Versmold; Christoph Engel; Alfons Meindl; Norbert Arnold; Wera Hofmann; Christian Sutter; Dieter Niederacher; Helmut Deissler; Trinidad Caldes; Kati Kämpjärvi; Heli Nevanlinna; Jacques Simard; Jonathan Beesley; Xiaoqing Chen; Susan L Neuhausen; Timothy R Rebbeck; Theresa Wagner; Henry T Lynch; Claudine Isaacs; Jeffrey Weitzel; Patricia A Ganz; Mary B Daly; Gail Tomlinson; Olufunmilayo I Olopade; Joanne L Blum; Fergus J Couch; Paolo Peterlongo; Siranoush Manoukian; Monica Barile; Paolo Radice; Csilla I Szabo; Lutecia H Mateus Pereira; Mark H Greene; Gad Rennert; Flavio Lejbkowicz; Ofra Barnett-Griness; Irene L Andrulis; Hilmi Ozcelik; Anne-Marie Gerdes; Maria A Caligo; Yael Laitman; Bella Kaufman; Roni Milgrom; Eitan Friedman; Susan M Domchek; Katherine L Nathanson; Ana Osorio; Gemma Llort; Roger L Milne; Javier Benítez; Ute Hamann; Frans B L Hogervorst; Peggy Manders; Marjolijn J L Ligtenberg; Ans M W van den Ouweland; Susan Peock; Margaret Cook; Radka Platte; D Gareth Evans; Rosalind Eeles; Gabriella Pichert; Carol Chu; Diana Eccles; Rosemarie Davidson; Fiona Douglas; Andrew K Godwin; Laure Barjhoux; Sylvie Mazoyer; Hagay Sobol; Violaine Bourdon; François Eisinger; Agnès Chompret; Corinne Capoulade; Brigitte Bressac-de Paillerets; Gilbert M Lenoir; Marion Gauthier-Villars; Claude Houdayer; Dominique Stoppa-Lyonnet; Georgia Chenevix-Trench; Douglas F Easton
Journal:  Am J Hum Genet       Date:  2008-03-20       Impact factor: 11.025

7.  Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.

Authors:  Mieke Kriege; Cecile T M Brekelmans; Carla Boetes; Peter E Besnard; Harmine M Zonderland; Inge Marie Obdeijn; Radu A Manoliu; Theo Kok; Hans Peterse; Madeleine M A Tilanus-Linthorst; Sara H Muller; Sybren Meijer; Jan C Oosterwijk; Louk V A M Beex; Rob A E M Tollenaar; Harry J de Koning; Emiel J T Rutgers; Jan G M Klijn
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

8.  Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.

Authors:  Ellen Warner; Donald B Plewes; Kimberley A Hill; Petrina A Causer; Judit T Zubovits; Roberta A Jong; Margaret R Cutrara; Gerrit DeBoer; Martin J Yaffe; Sandra J Messner; Wendy S Meschino; Cameron A Piron; Steven A Narod
Journal:  JAMA       Date:  2004-09-15       Impact factor: 56.272

9.  BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.

Authors:  Marie Soegaard; Susanne Kruger Kjaer; Mark Cox; Eva Wozniak; Estrid Høgdall; Claus Høgdall; Jan Blaakaer; Ian J Jacobs; Simon A Gayther; Susan J Ramus
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

10.  Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.

Authors:  D Gareth Evans; Andrew Shenton; Emma Woodward; Fiona Lalloo; Anthony Howell; Eamonn R Maher
Journal:  BMC Cancer       Date:  2008-05-30       Impact factor: 4.430

View more
  6 in total

1.  Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.

Authors:  Mandy L Ballinger; Ana Best; Phuong L Mai; Payal P Khincha; Jennifer T Loud; June A Peters; Maria Isabel Achatz; Rubens Chojniak; Alexandre Balieiro da Costa; Karina Miranda Santiago; Judy Garber; Allison F O'Neill; Rosalind A Eeles; D Gareth Evans; Eveline Bleiker; Gabe S Sonke; Marielle Ruijs; Claudette Loo; Joshua Schiffman; Anne Naumer; Wendy Kohlmann; Louise C Strong; Jasmina Bojadzieva; David Malkin; Surya P Rednam; Elena M Stoffel; Erika Koeppe; Jeffrey N Weitzel; Thomas P Slavin; Bita Nehoray; Mark Robson; Michael Walsh; Lorenzo Manelli; Anita Villani; David M Thomas; Sharon A Savage
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

2.  Screening magnetic resonance imaging recommendations and outcomes in patients at high risk for breast cancer.

Authors:  Sima Ehsani; Roberta M Strigel; Erica Pettke; Lee Wilke; Amye J Tevaarwerk; Wendy B DeMartini; Kari B Wisinski
Journal:  Breast J       Date:  2015-03-17       Impact factor: 2.431

3.  High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series.

Authors:  Pål Møller; Lovise Mæhle; Lars F Engebretsen; Trond Ludvigsen; Christoffer Jonsrud; Jaran Apold; Anita Vabø; Neal Clark
Journal:  Hered Cancer Clin Pract       Date:  2010-01-19       Impact factor: 2.857

4.  Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls.

Authors:  Sibel Saya; Emma Killick; Sarah Thomas; Natalie Taylor; Elizabeth K Bancroft; Jeanette Rothwell; Sarah Benafif; Alexander Dias; Christos Mikropoulos; Jenny Pope; Anthony Chamberlain; Ranga Gunapala; Louise Izatt; Lucy Side; Lisa Walker; Susan Tomkins; Jackie Cook; Julian Barwell; Vicki Wiles; Lauren Limb; Diana Eccles; Martin O Leach; Susan Shanley; Fiona J Gilbert; Helen Hanson; David Gallagher; Bala Rajashanker; Richard W Whitehouse; Dow-Mu Koh; S Aslam Sohaib; D Gareth Evans; Rosalind A Eeles
Journal:  Fam Cancer       Date:  2017-07       Impact factor: 2.375

5.  Final Results of the Prospective FH02 Mammographic Surveillance Study of Women Aged 35-39 at Increased Familial Risk of Breast Cancer.

Authors:  D G Evans; S Thomas; J Caunt; A Burch; A R Brentnall; L Roberts; A Howell; M Wilson; R Fox; S Hillier; D M Sibbering; S Moss; M G Wallis; D M Eccles; S Duffy
Journal:  EClinicalMedicine       Date:  2019-01

6.  Breast cancer risk assessment in 8,824 women attending a family history evaluation and screening programme.

Authors:  D Gareth R Evans; Sarah Ingham; Sarah Dawe; L Roberts; F Lalloo; A R Brentnall; P Stavrinos; Anthony Howell
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.